TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06238219

Intervention type: DRUG
Intervention: Neuromuscular Blocking Agent
Description: Administration of any neuromuscular blocking agent for surgery under general anesthesia
Study: NCT05900908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamma Tile-Surgically Targeted Radiation Therapy (STaRT)
Description: GammaTiles are a permanently implanted radiation device consisting of Cs-131 seeds positioned within a collagen tile

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiation Therapy
Description: External Beam Radiation Therapy
Study: NCT05573464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI HFO 320/14.4/9.6 μg
Description: Budesonide, Glycopyrronium, and Formoterol Fumarate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BGF MDI HFA 320/14.4/9.6 μg
Description: Budesonide, Glycopyrronium, and Formoterol Fumarate
Study: NCT04783233

Intervention type: BIOLOGICAL
Intervention: Chitosan succinamide
Description: Chitogel will be tested for suitability as a packing material in tympanoplasty surgery.

Intervention type: BIOLOGICAL
Intervention: Gelfoam
Description: Gelfoam is the current packing material for tympanoplasty surgery.
Study: NCT06551298

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menggongzi Tibetan Tea Special Drink
Description: Menggongzi Tibetan Tea Special Drink (50ml/time, taken after breakfast and lunch)+Low fat diet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Calcium 20Mg Tab
Description: Atorvastatin Calcium Tablets (20mg, qn)+Low Fat Diet

Intervention type: OTHER
Group type: OTHER
Intervention: Low fat diet
Description: Low fat diet
Study: NCT06351553

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation exclusively with radiofrequency
Description: The QDOT (Biosense Webster, Inc.) or TactiFlex (Abbott S.E.) catheters will be used. The ablation will be controlled by temperature, with a limit of 42ºC and a power target of 30-40W. A high-power strategy (90 W/4 seconds) can be used on the posterior wall when the QDOT catheter is used.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation exclusively with pulsed field ablation
Description: The Sphere-9 catheter will be used (with biphasic and unipolar wave), with a duration per application of 5 seconds and a separation between lesions of 5-6mm. The target temperature increase will be at least 1.5ºC above the patient's basal temperature to mark the ablation as effective.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined pulmonary vein isolation
Description: The Sphere-9 catheter will be used for both radiofrequency and pulsed field ablation. When using radiofrequency, the ablation will be temperature controlled, with a target temperature of 73ºC. The duration per application will be 5 seconds. Catheter irrigation during ablation will be 30ml/min, with a maximum current intensity of 3700mA, and a maximum current density of 13.6mA/mm2. The separation between lesions will be 7-8mm. Regarding pulsed field ablation, the characteristics will be those indicated in Pulmonary vein isolation exclusively with pulsed field ablation group.
Study: NCT03613792

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Opioid analgesic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Opioid analgesic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Benzodiazepine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Analgesic
Study: NCT05222204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel
Description: intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel in patients with pancreatic cancer with peritoneal metastasis
Study: NCT05352880

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: serum magnesium level, FEMg
Description: Blood (serum) for: Magnesium (Mg).Urea, creatinine. Calcium (ca), phosphorus (ph).Sodium (Na), potassium (k), chloride (CL).Fasting blood glucose, cholesterol, triglycerides. Intact PTH, 25OH vitamin D.uric acid, albumin. CBC.~Trough level of cyclosporine or tacrolimus. ii. Urine for:24 hour urinary: Mg, Ca, Ph, Cl and protein. Spot urine sample to calculate fractional excretion of Mg (FEmg)~. Detailed history taking, Thorough Systemic physical examination.
Study: NCT04730401

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma from COVID-19 donors
Description: Convalescent plasma from COVID-19 donors

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Convalescent plasma from COVID-19 donors
Description: Convalescent plasma from COVID-19 donors

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200mL saline
Study: NCT04825756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manualized equine assisted therapy
Description: This equine assisted therapy (EAT), which is delivered in a group setting, combines therapeutic horseback riding with cognitive behavioral strategies for anxiety. Each 45 minute session is delivered in a group format with up to four children between 6 and 17 years of age. Each session follows the same structure: (1) weekly review; (2) groom and connect; (3) warm-up period; (4) session activity; (5) cool down; (6) parent/caregiver psychoeducation, during which the instructor facilitates psychoeducation; and (7) homework instruction.
Study: NCT03924102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardiac Perfusion and Metabolism with [11C] Acetate PET/CT
Description: A rest and stress imaging study will be conducted on the PET/CT scanner with \[11C\] Acetate.
Study: NCT04724447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: 2 x 450mg VGCV tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo equivalent of 900mg/day VGCV
Study: NCT06078644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: respiratory exercise diary
Description: Patients in the intervention group will be asked to perform breathing exercises in the form of using a spirometer 10 times every hour during the preoperative period while they are awake for three days, starting from the first day after the surgery. Patients in this group will be given a breathing exercise diary.
Study: NCT05050786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Wound Pressure Therapy (Prevena(TM))
Description: After skin closure, NPWT in the form of Prevena™ (KCI/Acelity, San Antonia, TX, USA) is applied using the following technique: The sterile foam dressing is removed from the package and placed on the incision in the entire length, on top of which the sterile dressing is placed, ensuring air tightness. An appropriate hole in the dressing is cut at the center of the dressing and the tube for the interface pad is connected and a negative pressure of 125mmHg is applied. The Prevena™ system is removed on the morning of postoperative day 3.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Wound Dressing
Description: After skin closure, a standard operative dressing is applied in the entire length of the incision. This operative dressing is removed in the morning of postoperative day two. Only in the case of blood or serous fluid mandating changing of the dressing, will this be done prior to postoperative day 2.
Study: NCT05673668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular Denervation System (Netrod)
Description: The Netrod system is a percutaneous, catheter- based device which uses radiofrequency energy to denervate the sympathetic nerves surrounding the arteries
Study: NCT06439472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suboccipital Inhibition Technique
Description: The researcher will place their palms under the patient's head and use their fingers to contact the occipital condyles. Next, the researcher will place the 3rd and 4th fingers of each hand in the space between the occiput and the spinous process of C2. The metacarpophalangeal joints are at 90º flexion, with the base of the skull resting on their hands while they apply constant, non-painful pressure in a postero-anterior direction, keeping the 2nd, 3rd and 4th fingers together in extension. Afterwards, the researcher applies a light and gentle traction in a cephalad direction in order to relieve the suboccipital area. Once the suboccipital muscles have relaxed, the researcher gently removes the contact, leaving the participant's head resting on the table.~This technique is performed for 4 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Technique
Description: The participant is instructed to lie down in the supine position while the mediator assumes a position at the head of the table and places their hands on the participant's shoulders. This technique is performed for 4 minutes.
Study: NCT06063161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy intervention
Description: Music therapy intervention administered for 30 minutes 3x/week by certified music therapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-guided music listening
Description: Participants will listen to generic music playlists.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: placebo arm, routine standard of care
Study: NCT04926285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine
Description: Escalating doses of Omacetaxine 0.625 mg/m2 q12h, 1.25 mg/m2 q12h, 2.0 mg/m2 q12h, and 2.5 mg/m2 q12h
Study: NCT05833646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group 1
Description: In each group, patients will be applied both standard subcutaneous heparin injection and with ShotBlocker.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group 2
Description: In each group, patients will be applied both standard subcutaneous heparin injection and with virtual reality glasses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group 3
Description: In each group, patients will be applied both standard subcutaneous heparin injection and with cold application.
Study: NCT05431777

Intervention type: DRUG
Intervention: Avelumab
Description: As provided in real world setting
Study: NCT06422442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Threat-related stimulus exposure
Description: Participants will view threat-related stimuli (words or faces) paired with nonthreat matches in three related experimental paradigms.
Study: NCT06134336

Intervention type: OTHER
Intervention: Interview
Description: No interventional or behavioral intervention will be applied. Only interviews will be conducted through a questionnaire.

Intervention type: OTHER
Intervention: Interview
Description: No interventional or behavioral intervention will be applied. Only interviews will be conducted through a questionnaire.
Study: NCT05215899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MINDFULNESS-BASED YOGA AND MEDITATION
Description: The application was carried out by the researcher who had completed mindfulness-based yoga and meditation training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MINDFULNESS-BASED YOGA AND MEDITATION
Description: The application was carried out by the researcher who had completed mindfulness-based yoga and meditation training.
Study: NCT06412562

Intervention type: DIAGNOSTIC_TEST
Intervention: The Maudsley 3-item Visual Analogue Scale (M3VAS)
Description: Patients will be asked to complete The Maudsley 3-item Visual Analogue Scale (M3VAS) and 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR-16).
Study: NCT05858684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC012F injection
Description: Each subject will receive GC012F injection (CD19-BCMA CAR-T cells) by intravenous infusion on Day 0.
Study: NCT04642352

Intervention type: DRUG
Intervention: superior laryngeal nerve block
Description: A unilateral injection of 2 cc of a 1:1 mixture of 0.25% bupivacaine and Kenalog-40 via a 27 gauge needle to the thyrohyoid space (front of neck, just above larynx/voice box) via a 27 gauge needle to the thyrohyoid space (front of neck, just above larynx/voice box) on the side which exhibited most discomfort/tenderness/cough on palpation. If neither side was uncomfortable, the right side will be used.
Study: NCT04926285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine
Description: Escalating doses of Omacetaxine 0.625 mg/m2 q12h, 1.25 mg/m2 q12h, 2.0 mg/m2 q12h, and 2.5 mg/m2 q12h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine
Description: Escalating doses of Omacetaxine 0.625 mg/m2 q12h, 1.25 mg/m2 q12h, 2.0 mg/m2 q12h, and 2.5 mg/m2 q12h
Study: NCT05707910

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV immunological agent
Description: Low-dose group:2\*10\^7 Medium-dose group:5\*10\^7 High-dose group:2\*10\^8
Study: NCT04926285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine
Description: Escalating doses of Omacetaxine 0.625 mg/m2 q12h, 1.25 mg/m2 q12h, 2.0 mg/m2 q12h, and 2.5 mg/m2 q12h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax at 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax at 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax at 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax at 400mg
Study: NCT05500014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofortified potato, not genetically modified
Description: Cooked potato, not genetically modified, with the addition of an acqueous solution of 57FeSO4 (3 mg in total).
Study: NCT04792060

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hook plate
Description: We used titanium 2.4 mm hooked distal ulnar locked plate used for fixation of distal ulna fractures , this plate have low profile which is anatomically precontoured
Study: NCT05719298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory interface
Description: Application of the new interface and accessories and provision of non-invasive respiratory support through the device.
Study: NCT05745753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sample blood
Description: At the time of enrolment, peripheral blood sampling is expected at the outpatient clinic of the experimental center and the study of the patient's clinical history.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sample blood
Description: At the time of enrolment, peripheral blood sampling is expected at the outpatient clinic of the experimental center and the study of the patient's clinical history.
Study: NCT05085470

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Schistosoma mansoni infection
Description: 20 viable male Schistosoma mansoni cercariae of the Puerto Rican strain

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Schistosoma mansoni infection
Description: 20 viable male Schistosoma mansoni cercariae of the Puerto Rican strain

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo mock infection
Description: Placebo mock infection with water
Study: NCT05262751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofev®
Description: Ofev®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofev®
Description: Ofev®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib formulation 1
Description: Nintedanib formulation 1: Monolithic Nintedanib Modified Release Tablet (MR1) as two Prototypes (MR1-1 and MR1-2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib formulation 2
Description: Nintedanib formulation 2: Polyox Nintedanib Modified Release Tablet (MR2) as two Prototypes (MR2-1 and MR2-2).
Study: NCT05284630

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise follow up with mobile application
Description: Exercises will be followed by mobile application. Electrotherapy will be performed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-Based Exercise Program followed by paper booklet
Description: Exercise will be followed by paper booklet. Electrotherapy will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrotherapy
Description: Electrotherapy will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrotherapy
Description: Electrotherapy will be performed.
Study: NCT06026553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac (Toradol)
Description: IV Ketorolac (Toradol) will be administered at conclusion of oocyte retrieval. All enrolled patients will receive standard post-operative pain management.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: IV Placebo (saline) will be administered at conclusion of oocyte retrieval. All enrolled patients will receive standard post-operative pain management.
Study: NCT05517226

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cotadutide
Description: Participants will receive cotadutide subcutaneously.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cotadutide
Description: Participants will receive cotadutide subcutaneously.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cotadutide
Description: Participants will receive cotadutide subcutaneously.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cotadutide
Description: Participants will receive cotadutide subcutaneously.
Study: NCT04366505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU) and neurofeedback (NFB)
Description: This group will receive Treatment as usual (TAU) and neurofeedback (NFB). During NFB, participants will be asked to regulate the signal from a target brain region during the presentation of alcohol cues. The ventral striatum was chosen as target region.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based relapse prevention (MBRP) and NFB
Description: This group will receive MBRP and neurofeedback (NFB). MBRP consists of 5 extensive sessions of a specific manualized mindfulness-based intervention for alcohol dependent patients which will be carried out by trained psychologists and psychotherapists. During NFB, participants will be asked to regulate the signal from a target brain region during the presentation of alcohol cues. The ventral striatum was chosen as a target region.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU and sham NFB
Description: This group will receive TAU and sham NFB. Sham NFB means that the signal displayed to the participant is based on activity in a control region, the auditory cortex, which is not involved in cue reactivity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBT and sham NFB
Description: This group will receive MBRP and sham NFB. MBRP consists of 5 extensive sessions of a specific manualized mindfulness-based intervention for alcohol dependent patients which will be carried out by trained psychologists and psychotherapists. Sham NFB means that the signal displayed to the participant is based on activity in a control region, the auditory cortex, which is not involved in cue reactivity.
Study: NCT05017077

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DynaVision System
Description: Telemonitoring for pediatric heart failure
Study: NCT06198972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Pnf exercises
Description: Exercise Frequency 3 days/week Exercise Intensity 60% of 1 maximum repetition Exercise Duration: 5-minute warm-up 20 minutes (2 sets of 15 repetitions) exercise training 5 min cool down Exercise Type Pelvic patterns~* Anterior elevation-Posterior depression~* Anterior depression-Posterior elevation PNF techniques~* Repetitive stretching~* Rhythmic stabilization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength exercises
Description: 3 days/week 60% of 1 repetition maximum 5 minute warm up 20 min exercise training 5 min cool down Lower extremity movements~* Hip flexion~* Hip extension~* Hip abduction~* Hip adduction~* Knee flexion~* Knee extension Resistance exercise training
Study: NCT05447234

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tcrx T cell
Description: Sequential IV infusion
Study: NCT04921449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ED Physical Therapy
Description: All ED Physical Therapy treatment classifications involve a combination of exercise, range of motion, education, prognostic guidance, and reassurance. Patients are provided with an individualized home exercise plan based on their matched treatment classification and/or active rest.
Study: NCT04682379

Intervention type: DIAGNOSTIC_TEST
Intervention: Proprioceptive assessment
Description: 1. Trunk flexion-extension repositioning test~2. Trunk lateral-flexion repositioning test~3. Trunk axial-rotation repositioning test~4. Neck rotation repositioning test~5. Elbow flexion repositioning test~6. Knee extension repositioning test

Intervention type: DIAGNOSTIC_TEST
Intervention: Proprioceptive assessment
Description: 1. Trunk flexion-extension repositioning test~2. Trunk lateral-flexion repositioning test~3. Trunk axial-rotation repositioning test~4. Neck rotation repositioning test~5. Elbow flexion repositioning test~6. Knee extension repositioning test
Study: NCT03885245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-ctirulline
Description: 7 weeks of treatment with 15 g/day of orally administered (powder form mixed with water) L-citrulline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: 7 weeks of treatment with orally administered matching placebo (to 15 g/day of L-citrulline)
Study: NCT04921449

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Includes any diagnostic imaging, patient education and reassurance, and administration or prescribing of analgesic medications, as per the treating physician's usual and customary practice.